Cizzle Biotechnology Holdings PLC (CIZ) AI Stock Analysis

• Market Cap: £7.14M
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 396,391,780
• 10 Day Avg. Volume: 655,017
• 30 Day Avg. Volume: 1,232,506
• PEG Ratio: 0.00
• Price to Book (P/B): 73.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 1.50 p ▼(-3.23% Downside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.

Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model

Company Description

Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Cizzle Biotechnology’s monetization is expected to come from commercializing its lung-cancer diagnostic test(s), typically through a combination of (a) selling test kits or assay components to laboratories/healthcare providers, (b) earning fees per test performed (if the company or a partner runs the test as a service), and/or (c) licensing its biomarker/assay technology and related intellectual property to diagnostic or life-sciences partners in exchange for upfront payments, milestone payments, and royalties. Specific current revenue streams, the presence or terms of major commercial partnerships, and the extent of present-day product sales are null.

Cizzle Biotechnology Holdings PLC Financial Statement Overview

Summary

Pre-revenue with persistent operating losses and ongoing negative free cash flow. While cash burn is improving and debt is minimal, the sharp erosion of equity and shrinking asset base increase funding risk.

Income Statement

The company is still pre-revenue (revenue has been 0 across all reported years), which keeps profitability structurally weak. Losses have persisted every year, although net losses improved materially versus 2021 and were relatively small in 2023–2024. Operating losses (EBIT) remain sizable and fairly consistent (roughly ~£0.85m–£0.98m in 2021–2024), indicating an ongoing cost base without corresponding revenue traction.

Balance Sheet

Leverage is low with effectively no debt in recent years, which reduces financial risk. However, the balance sheet has weakened notably: shareholders’ equity fell sharply from £2.64m (2022) to £1.51m (2023) and then to just £0.082m (2024), shrinking the capital cushion. Total assets also declined materially over the same period, and returns on equity remain negative due to continuing losses.

Cash Flow

Cash burn remains a key issue: operating cash flow and free cash flow are negative every year. There is improvement in the run-rate (free cash flow improved from -£0.872m in 2022 to -£0.639m in 2023 and -£0.358m in 2024), suggesting better cost control or lower spending, but the business is still consuming cash with no operating inflows. Year-to-year free cash flow growth is volatile, reflecting an uneven spending profile typical of early-stage biotech.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	0.00	0.00	0.00	-963.00K	-3.96M	-306.00K
Net Income	-1.12K	-2.17K	-1.72K	-910.00K	-3.92M	-306.00K
Balance Sheet
Total Assets	257.00K	492.00K	1.69M	2.79M	1.16M	90.00K
Cash, Cash Equivalents and Short-Term Investments	182.00K	387.00K	1.56M	478.00K	875.00K	84.00K
Total Debt	150.00K	0.00	0.00	0.00	0.00	10.00K
Total Liabilities	533.00K	410.00K	186.00K	145.00K	218.00K	58.00K
Stockholders Equity	-276.00K	82.00K	1.51M	2.64M	937.00K	32.00K
Cash Flow
Free Cash Flow	-333.12K	-358.00K	-639.00K	-872.00K	-1.21M	-294.00K
Operating Cash Flow	-331.12K	-358.00K	-639.00K	-872.00K	-1.01M	-294.00K
Investing Cash Flow	-2.00K	0.00	0.00	-120.00K	-154.00K	0.00
Financing Cash Flow	151.00K	579.00K	305.00K	595.00K	2.03M	10.00

Cizzle Biotechnology Holdings PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£6.98M	-0.92	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCF	49 Neutral	£4.41M	-0.88	-53.79%	―	―	85.56%
CIZ	43 Neutral	£7.14M	-4,173.96	-433.59%	―	―	―
OPTI	43 Neutral	£6.56M	-2.61	-2.42%	―	―	―
NFX	42 Neutral	£5.22M	-5.98	-153.80%	―	―	-616.67%
VAL	41 Neutral	£2.23M	―	―	―	418.49%	27.86%

Cizzle Biotechnology Holdings PLC Corporate Events

Cizzle Biotechnology Secures Extra Royalties as U.S. Lung Cancer Test Nears Launch

Cizzle Biotechnology reported progress toward the U.S. commercial launch of its CIZ1B blood test for early lung cancer detection, as North American partner Cizzle Bio Inc. nears completion of validation work with Omni Health Diagnostics in Texas ahead of a planned CLIA accreditation application in the second quarter of 2026. The partners have also revised their financial arrangements, confirming that Cizzle will receive the remaining US$1.81m of initial advance royalty payments by end-2026 and securing an additional minimum US$3.5m in guaranteed royalties from 2031, underpinning at least US$5.9m in contracted income and supporting the long-term rollout of the test across North America.

The most recent analyst rating on (GB:CIZ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Cizzle Biotechnology Holdings PLC stock, see the GB:CIZ Stock Forecast page.

Cizzle Secures Canadian Patent to Fortify Global Lung Cancer Test Rollout

Canadian approval for Cizzle’s CIZ1B patent reinforces the company’s proprietary two-step lung cancer test, bolstering its licensing partner Cizzle Bio Inc’s commercial rollout in North America and supporting ambitions for broader global protection alongside expected U.S. grants. The strengthened intellectual property underpins Cizzle’s strategy to align with early-detection initiatives, particularly the NHS cancer plan, positioning the firm to deepen partnerships with clinical laboratories and hospitals and to safeguard shareholder value through exclusive technology deployment.

The most recent analyst rating on (GB:CIZ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Cizzle Biotechnology Holdings PLC stock, see the GB:CIZ Stock Forecast page.